Plasmid to Produce Recombinant SARS-CoV-2 Nucleocapsid Protein

Opportunity

Available for Licensing and Collaboration

Direct Purchase at Kerafast –
Individual Product Link Below!

Inventor

Brian Geiss

At A Glance

​Researchers at Colorado State University have developed a plasmid and purification protocol for the expression and purification of a soluble SARS-CoV-2 nucleocapsid protein for use in diagnostic assays, in response to the SARS-CoV-2/COVID-19 outbreak.

Follow the link to find more details about the product and purchase, or contact our office directly for information about collaboration and licensing opportunities.

Licensing Director

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

Reference No.:  2020-090

SARS-CoV-2 Nucleocapsid Protein Expression Plasmid
pBG690 SARS-CoV-2 Nucleocapsid Protein Expression Plasmid

Highlights:

  • Bacterial expression plasmid encodes a bacterial codon-optimized fragment of the SARS-CoV-2 nucleocapsid protein
  • Plasmid was sequence verified
  • Bacterial expression protocol can produce monomeric nucleocapsid protein (as confirmed by mass spectroscopy) with greater than 95% purify
  • Purified nucleocapsid protein has been tested by collaborators for antigenicity in mice immunized against the recombinant protein as well as bats infected with SARS-CoV-2
  • Protein expressed and purified from this plasmid is antigenic
  • Protein can be used for ELISAs as well as other assays to indicate presence of SARS-CoV-2 nucleocapsid protein antibodies in patient samples
Benefits / Applications
  • Plasmid can be licensed for in-house production – allows for larger amounts of antigen for diagnostic testing
  • SARS-CoV-2 nucleoprotein is a major diagnostic antigen for detection of active infection and immunity

Last updated: April 2020

Add keywords or various names of inventors here (text is hidden)

#CSUInvents – #TechTuesday! In response to the #sarscov2#covid19 outbreak, researchers at Colorado State University, department of CSU Microbiology, Immunology & Pathology have developed a plasmid and purification protocol for the expression and purification of a soluble #SARS-CoV-2 nucleocapsid #protein for use in #diagnostics. This nucleoprotein is a major #diagnostic antigen for detection of active #infection and #immunity. Plasmid available for #licensing.

Inventor: Brian GeissCSU College of Veterinary Medicine and Biomedical Sciences.

#covid19research #publichealth #autm #flc #innovation #infectiousdiseases #infectioncontrol #MIP #CSU

Centers for Disease Control and PreventionThe National Institutes of HealthColorado BioScience Association

https://lnkd.in/eBGvXTz